RegeneRx Collaborators Receive Notice of Allowance of U.S. Patent for the Treatment of Peripheral Neuropathy

Tuesday, June 13, 2017 General News
Email Print This Page Comment bookmark
Font : A-A+

Research Conducted Under Material Transfer Agreement Provides Potential Therapeutic Target for RGN-352

ROCKVILLE, Md., June 13, 2017 /PRNewswire/ -- RegeneRx Biopharmaceuticals, Inc. (OTCQB: RGRX)

("the Company" or "RegeneRx"), a clinical-stage drug development company focused on tissue protection, repair and regeneration, today announced that a Notice of Allowance has been received from the U.S. Patent and Trademark Office (USPTO) related to the composition and use of Thymosin beta 4 (T?4) and certain of its peptide constituents.  T?4 is the active pharmaceutical ingredient in RegeneRx's proprietary drug candidate, RGN-352, a first-in-class product candidate for the treatment of peripheral neuropathy. 

Peripheral neuropathy is a condition that develops as a result of damage to the peripheral nervous system, the communications network that transmits information between the brain and spinal cord to other parts of the body.  Symptoms can range from numbness or tingling, to pricking sensations, or muscle weakness.  It is estimated that 20 million people in the United States have some form of peripheral neuropathy with an increased incidence in patients with diabetes. 

The patent will be issued to Dr. Michael Chopp and his colleagues at the Henry Ford Hospital System (HFHS) in Detroit, Michigan, and is the subject of a license agreement between RegeneRx and HFHS.  Dr. Chopp and his team have published several scientific articles demonstrating that T?4 can ameliorate the effects of diabetic peripheral neuropathy in animal models of the disease.  RegeneRx is responsible for all patent fees and commercialization of potential products. The patent will expire in December 2032, not including any possible extensions by the USPTO.

"This patent continues to expand the scope of potential use of RGN-352, our systemic formulation of T?4, in patients with neural injury and disease. The neurovascular remodeling, repair and regeneration properties of T?4 found by Dr. Chopp and his team in their animal models elaborate the considerable potential for the use of T?4 in major disorders such as diabetic-induced peripheral neuropathy and other conditions or diseases that are associated with nerve damage," stated J.J. Finkelstein, RegeneRx's president and chief executive officer.    

About RegeneRx Biopharmaceuticals, Inc. (www.regenerx.com)

RegeneRx is focused on the development of novel therapeutic peptides, including Thymosin beta 4 (T?4) and its constituent fragments, for tissue and organ protection, repair and regeneration. RegeneRx currently has three drug candidates in clinical development for ophthalmic, cardiac and dermal indications, three active strategic licensing agreements in the U.S., China, and Pan Asia (Korea, Japan, and Australia, among others), and has patents and patent applications covering its products in many countries throughout the world.

RGN-259, the Company's T?4-based ophthalmic drug candidate, has been designated an orphan drug in the U.S. for the treatment of neurotrophic keratopathy (NK). In September 2016, RegeneRx, through its U.S joint venture, ReGenTree LLC, began enrollment in its second Phase 3 clinical trial in approximately ~500 patients with dry eye syndrome, which is expected to be completed in the fourth quarter of 2017. The Company is simultaneously conducting a 46-patient Phase 3 clinical trial in patients with NK targeted for completion in 2018.  RGN-259 is also being developed in patients with dry eye syndrome in Asia through RegeneRx's two Asian partnerships.  

RGN-352, the Company's T?4-based injectable formulation, is a Phase 2-ready drug candidate designed to be administered systemically to prevent and repair cardiac damage resulting from heart attacks and central nervous system tissue damage associated disorders such as peripheral neuropathy, multiple sclerosis and traumatic brain injuries such as stroke.

RGN-137, also designated an orphan drug in the U.S., is the Company's T?4-based dermal gel formulation that is being developed for epidermolysis bullosa, a rare skin condition. The Company's licensee, GtreeBNT, is sponsoring a phase 3 clinical trial in the U.S. and is expected to initiate the study in the third quarter of 2017.

For additional information about RegeneRx please visit www.regenerx.com.

Forward-Looking Statements

Any statements in this press release that are not historical facts are forward-looking statements made under the provisions of the Private Securities Litigation Reform Act of 1995. Any forward-looking statements involve risks and uncertainties that could cause actual results to be materially different from historical results or from any future results expressed or implied by such forward-looking statements. There can be no assurance that any notices or patents issued by any government patent authority in any country, or licenses held by the Company, or patent applications filed by the Company, including this most recent Notice of Allowance in the United States, or any current or future clinical trials will result in approved products or future value. Please view these and other risks described in the Company's filings with the Securities and Exchange Commission ("SEC"), including those identified in the "Risk Factors" section of the annual report on Form 10-K for the year ended December 31, 2016, and subsequent quarterly reports filed on Form 10-Q, as well as other filings it makes with the SEC. Any forward-looking statements in this press release represent the Company's views only as of the date of this release and should not be relied upon as representing its views as of any subsequent date.  The Company specifically disclaims any obligation to update this information, as a result of future events or otherwise, except as required by applicable law.

To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/regenerx-collaborators-receive-notice-of-allowance-of-us-patent-for-the-treatment-of-peripheral-neuropathy-300472912.html

SOURCE RegeneRx Biopharmaceuticals, Inc.



Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
* Your comment can be maximum of 2500 characters
I agree to the terms and conditions

News A - Z

A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

News Search

Medindia Newsletters

Subscribe to our Free Newsletters!

Terms & Conditions and Privacy Policy.

Find a Doctor

Press Release Category

Press Release Archive

Stay Connected

  • Available on the Android Market
  • Available on the App Store

Facebook